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Abstract
Background: Although the management of sarcoma is improving, non adherence to clinical practice guidelines
(CPGs) remains high, mainly because of the low incidence of the disease and the variety of histological subtypes.
Since little is known about the health economics of sarcoma, we undertook a cost-effectiveness analysis (within the
CONnective TIssue CAncer NETwork, CONTICANET) comparing costs and outcomes when clinicians adhered to
CPGs and when they did not.
Methods: Patients studied had a histological diagnosis of sarcoma, were older than 15 years, and had been
treated in the Rhône-Alpes region of France (in 2005/2006) or in the Veneto region of Italy (in 2007). Data
collected retrospectively for the three years after diagnosis were used to determine relapse free survival and health
costs (adopting the hospital’s perspective and a microcosting approach). All costs were expressed in euros (€)a t
their 2009 value. A 4% annual discount rate was applied to both costs and effects. The incremental cost-
effectiveness ratio (ICER) was expressed as cost per relapse-free year gained when management was compliant
with CPGs compared with when it was not. To capture uncertainty surrounding ICER, a probabilistic sensitivity
analysis was performed based on a non-parametric bootstrap method.
Results: A total of 219 patients were included in the study. Compliance with CPGs was observed for 118 patients
(54%). Average total costs reached 23,571 euros when treatment was in accordance with CPGs and 27,313 euros
when it was not. In relation to relapse-free survival, compliance with CPGs strictly dominates non compliance, i.e. it
is both less costly and more effective. Taking uncertainty into account, the probability that compliance with CPGs
still strictly dominates was 75%.
Conclusions: Our findings should encourage physicians to increase their compliance with CPGs and healthcare
administrators to invest in the implementation of CPGs in the management of sarcoma.
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Sarcomas are rare tumours (accounting for only 1-2% of
all cancers) originating from connective tissue, skin, ret-
roperitoneum, bone and viscera [1]. The rarity of the
disease, along with the variety of histological types and
locations and the heterogeneity of prognostic factors
associated with local or distant spread, mean that physi-
cians have only limited personal experience of managing
the disease. Furthermore, outside centres of excellence,
there is little graduate or post-graduate medical training
in its optimum management. To improve the diagnosis
and prognosis of sarcoma, the European Commission
funded the Connective Tissue Cancer Network (CON-
TICANET) aimed at increasing the standardization of
diagnostic and therapeutic procedures.
In order to reduce inappropriate medical procedures,
Clinical Practice Guidelines (CPGs) were developed by
the Fédération Nationale des Centres de Lutte contre
le Cancer (the French Federation of Comprehensive
Cancer Centres) [2] and by the Italian National
Research Council [3]. France and Italy reached a con-
sensus in their CPGs relating to all phases of sarcoma
management (initial examination and diagnosis, histo-
pathological report, surgery, chemotherapy, and radia-
tion therapy) except surveillance after therapy (see
Annexe 1).
The impact of adherence to CPGs has received some
research attention [4-10], even in the management of
rare cancers [11-14]. However, little is known about the
financial impact of clinicians’ adherence to CPGs in gen-
eral, and the impact of adherence on outcomes and
costs of care has only rarely been simultaneously consid-
ered [15]. Such assessments are of particular value in
the current period of budgetary constraint, which pre-
vents the achievement of improved cancer outcomes
through increased health expenditure [16,17].
We therefore assessed the cost-effectiveness of com-
pliance with CPGs in sarcoma management by investi-
gating the relationship between health outcome and
resource consumption in patients treated in the regions
of the Rhône-Alpes in France and Veneto in Italy.
Methods
Study design
Our starting point was 327 sarcoma patients aged ≥ 15
years (254 in Veneto and 73 in Rhône-Alpes) diagnosed
over the relevant periods in the two regions. Absence of
patient consent, care undertaken outside the participat-
ing regions or in private hospitals, and missing records
(Table 1) reduced the number of patients included in
the study to 219, 58 from Rhône-Alpes and 161 from
Veneto. These patients were followed retrospectively for
the three years after sarcoma diagnosis or until the date
of death. All patients had histological confirmation of
primary malignant sarcoma, with or without distant
metastasis at initial diagnosis. With the exception of
osteosarcoma, sarcomatoid carcinoma, mesothelioma,
neuroblastoma, paraganglioma and mixed (epithelial and
mesenchymal) tumours of the female genital tract, all
histological subtypes were included. All patients in
Rhône-Alpes had been diagnosed between March 2005
and February 2006 and treated at the University Hospi-
tal of Lyon and/or at the Léon Bérard Cancer Centre.
All patients in Veneto had been diagnosed between Jan-
uary 2007 and December 2007 and treated in the public
hospitals of the region. Patients were managed in accor-
dance with the ethical principles for medical research
involving human subjects described in the Declaration
of Helsinki. The study received approval in France from
the National Ethics Committee (N°904073) and the
National Committee for Protection of Personal Data (N°
05-1102), and from the Local Sanitary Agency of the
Veneto Region and the Ethics Committee of the
Azienda Ospedaliera di Padova (N°156/06/CE) in Italy.
Each patient was required to give signed informed con-
sent. Lack of informed consent and treatment of sar-
coma outside the Veneto or Rhône-Alpes were
exclusion criteria. Cases of relapsed disease were also
excluded since CPGs for this setting are not available.
Clinical data
Hospital records were used to obtain data on the char-
acteristics of patients (age, sex, comorbidities) and their
sarcomas (visceral or soft tissue; superficial or deep
tumour); localization in lower or upper limb, head-neck
or trunk; histological subtype; major tumour diameter at
imaging and surgery; and grade). Data were also
obtained on resources utilization (using a micro-costing
approach) at diagnosis and during surgery (primary and
wide surgical resection), chemotherapy (drugs adminis-
tered in hospital or outpatient facilities) and radiother-
apy (sessions in hospital or outpatient facilities). We
also obtained data covering relapse or metastasis during
follow up, along with any subsequent need for surgical
interventions, chemotherapy and/or radiotherapy. Infor-
mation was collected on number of days of hospitaliza-
tion, use of pathology resources such as micro-biopsy
and cytology), use of imaging, and supportive treatments
such as antibiotics. The date of relapse was used to cal-
culate relapse free survival from diagnosis.
Physicians independent of the study (two from the
Léon Bérard Cancer Centre and two from the University
of Padua) assessed whether or not there had been com-
pliance with CPGs in each management phase covered
by such guidelines. Overall management was considered
to have been compliant only when CPGs had been
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up.
Costs and indicators of effectiveness
Costs were assessed for each patient and from the hos-
pital’s point of view for the period between diagnosis
and the end of follow-up or death [18]. Sources of unit
costs and prices are described in Table 2[19-21]. Days
of hospital admission were multiplied by the cost per
day (taking the average of the 2009 costs in France and
Italy). This covered the cost of personnel, medications
(except for chemotherapy and blood transfusions), use
of medical devices, laboratory tests, depreciation of
equipment and overheads. Doses of chemotherapy, and
number of transfusions, radiotherapy sessions, imaging
procedures, biopsies and consultations were multiplied
by their respective unit costs (again taking the average
of 2009 prices in France and Italy). Discounting of 4%
per year was applied. The mean costs were calculated
for patients whose overall management had been com-
pliant with CPGs and for patients in whom it had not.
Statistical analysis
Chi-square or t-tests were used, according to the type of
data, to compare compliant (CPG+) and non compliant
(CPG-) groups. Analysis of variance (ANOVA) was used
to explore the costs of overall management according to
histological subtype. Univariate survival analyses were
performed using the Kaplan-Meier method and the log-
rank test. The log-rank test was used to assess the effect
Table 1 Attrition of the study population
Region Eligible No consent Care outside the region Data not available
@ Included
Veneto 254 55 17 21 161
Rhône-Alpes 73 0 6 9 58
Total 327 55 23 30 219
@patients treated at private hospitals; missing clinical records
Table 2 Main unit costs and prices
Items Unit costs and prices Sources of information
Hospitalization (per day) 760,14€ Hospital Managers
Biopsy 51,45 € [19,20]
Consultation (external) 68,73€ [19,20]
Radiotherapy (per session) 94,21€ [19,20]
Chemo-therapy(per milligram of drugs) Caelix 17,74€ Hospital pharmacists
Carboplatin 0,21€ Hospital pharmacists
Cisplatin 0,32€ Hospital pharmacists
Deticene 0,03€ Hospital pharmacists
Doxorubicin 0,71€ Hospital pharmacists
Etopophos etoposide 0,16€ Hospital pharmacists
Gemcitabine 0,17€ Hospital pharmacists
Holoxan 0,07€ Hospital pharmacists
Ifosfamide 0,10€ Hospital pharmacists
Imatinib 0,24€ Hospital pharmacists
Melphalan 0,01€ Hospital pharmacists
Navelbine 1,91€ Hospital pharmacists
Oxaliplatin 3,92€ Hospital pharmacists
Paclitaxel 2,25€ Hospital pharmacists
Vincristine 7,16€ Hospital pharmacists
Transfusion (per pack) Ps 121,33€ [19,21]
Red blood cell 104,57€ [19,21]
Imaging(per exam.) Chest radiograph 22,49€ [19,20]
Colonoscopy 121,58€ [19,20]
Computed Tomography 83,20€ [19,20]
Ultrasound 50,48€ [19,20]
Magnetic Resonance Imaging 139,50€ [19,20]
Relapse-free survival three years after diagnosis was taken as the indicator of effectiveness. Mean relapse-free survival was calculated for CPG-compliant and non
compliant groups.
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confounding variables.
The incremental cost-effectiveness ratio (ICER),
expressing the incremental cost per additional relapse-
free year gained.
The uncertainty surrounding the ICER was captured
by a probabilistic sensitivity analysis according to proce-
dures established by the French National Authority for
Health (HAS) [22]. Ten thousand replications were
obtained by the non parametric bootstrap method. A
graphical representation of the sampling uncertainty
associated with the ICER on the cost-effectiveness plane
is shown in Figure 1[23]. The four quadrants of the
cost-effectiveness plane are as follows: northeast, com-
p l i a n c ew i t hC P G sm o r ec o s t l ya n dm o r ee f f e c t i v et h a n
non compliance; southeast, compliance less costly, more
effective; northwest (more costly, less effective) and
southwest (less costly, less effective). Confidence regions
were assessed and are represented by ellipses.
The outer ellipse defines the confidence region for the
mean cost difference and mean effect difference pair at
the 95% level and the inner ellipse at the 50% level. The
outer ellipse is equivalent to an acceptability region for
an inference test at 5% significance level whose null
hypothesis is the mean cost difference and mean effect
difference pair being equal to (0, 0). Consequently, if the
origin of the cost-effectiveness plane does not belong to
the confidence ellipse, then both the management of
patients with sarcoma (adherence versus non adherence
to CPGs) are significantly different regarding costs and
effects. For more robustness in the results, in addition
to confidence ellipses, uncertainty around the ICER was
taken into account by examining probabilities that it
belonged to each of the quadrants of the cost-effective-
ness plane.
Calculations were performed using STATA 11 and
Gauss software version 9.0.
Results
Table 3 shows the key characteristics of patients and the
health outcome in the whole of the study population
(219 cases) and in the CPG + (n = 118) and CPG- (n =
101) groups. Overall, age at diagnosis, ranging from 18
to 94 years, was in average 60 years and the majority of
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0.03% 75.12%
Figure 1 Probabilistic analysis of the ICER: scatter of points and confidence ellipses.
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Page 4 of 8patients studied (55%) were women. There was a variety
of histological types, the most frequent being Gastro
Intestinal Stromal Tumors(GIST) (26%), liposarcomas
(21%) and leiomyosarcomas (12%). Sixtythree percent of
tumors were of soft tissue, mostly in the trunk, and 81%
deep seated. Tumors had a mean size of 95 mm (range
3 to 450 mm). Tumors were grade II/III in 58% of
cases, Thirtytwo patients (15%) had previous cancers.
Differences between CPG compliant and non compliant
groups were significant for grade (there were more high
grade tumors in patients whose management did not
comply with CPGs, p = 0.01) and histological type (p =
0.03): CPGs was less likely in liposarcoma and leiomyo-
s a r c o m a .R e l a p s ef r e es u r v i v a lw a sam e a no f2 . 4 6y e a r s
in the CPG + group and 2.16 years in the non-compli-
ant group (p = 0.04).
Table 4 shows details of the mean costs in CPG + and
CPG- groups. The overall (for all 219 cases) cost of sar-
coma management per patient, ranging from €1,303 to
€107,464, reached €25,296 in average. Surgery (primary
and wide surgical excisions), with an average cost of
€8,170 represented 32% of the average total cost. Che-
motherapy (€6,107) accounted for 24% of the average
total cost, follow up (€5,048) for 20% of the average
total cost and diagnosis (€3,701) for 15%. Radiotherapy
(€2,270) represented 9% of the average total cost. Over-
all average cost per patient of managing sarcomas (all
subtypes included) was somewhat less in the GPG +
group than in the CPG- group, but the difference did
not reach statistical significance (p = 0.07). Overall aver-
age cost was significantly lower in the GPG + group
than in the CPG- group for GIST and dermatofibrosar-
coma (p < 0.01).
Table 5 shows that compliance with CPGs was less
costly and more effective than non compliance. On the
basis of the ICER point estimate, clinicians’ adherence
to CPGs in the management of patients with sarcoma
strictly dominates non adherence for relapse free survi-
val. Since the origin of the cost-effectiveness plane pre-
sented in Figure 1 was not included in the inner 95%
confidence ellipse, clinicians’ adherence versus non
adherence to CPGs is significantly different in terms of
cost and effectiveness. The probability of the ICER
belonging to each quadrant of the cost-effectiveness
plane is highest (75%) for the southeast quadrant, in
which compliance with CPG is both less costly and
more effective than non compliance. This is in accor-
dance with the results of Table 5 also concluding for
less costly and more effectiveness in compliant group.
Discussion
A weakness of the present study is that its retrospective
nature did not allow assessment of outcome in cost per
Quality Adjusted Life Year (QALY), as recommended by
the National Institute for Health and Clinical Excellence
(NICE) [24,25]. Notwithstanding this, freedom from
relapse undoubtedly contributes to quality of life in can-
cer patients.
Table 3 Clinical characteristics of patients by group: Mean ± SD or number of patients and (%)
Clinical characteristics All patients n = 219 CPG (+) n = 118 CPG (-) n = 101 p
Age (years) 60.4 ± 15.0 60.1 ± 15.3 60.7 ± 14.8 0.39
Sex (females) 121 (55.2%) 66 (56.0%) 55 (54.5%) 0.83
Previous cancer 32 (14.8%) 15 (12.8%) 17 (17.2%) 0.37
Tumour grade low (grade I) 38 (20.3%) 27 (27.6%) 11 (12.4%) 0.01
intermediate (grade II) 38 (20.3%) 18 (18.3%) 20 (22.5%)
high (grade III) 70 (37.5%) 27 (27.6%) 43 (48.3%)
not applicable 41 (21.9%) 26 (26.5%) 15 (16.8%)
Tumour site soft tissues 137 (62.6%) 71 (60.2%) 66 (65.4%) 0.43
viscera 82 (37.4%) 47 (39.8%) 35 (34.6%)
Tumour size in mm 94.6 ± 80.6 96.8 ± 91.4 91.9 ± 66.3 0.67
Tumour depth superficial 38 (18.9%) 22 (20.6%) 16 (17%) 0.52
depth deep 163 (81.1%) 85 (79.4%) 78 (83%)
Histology GIST 54 (25.6%) 37 (32.5%) 17 (17.5%) 0.03
Liposarcoma 45 (21.3%) 18 (15.8%) 27 (27.8%)
Leiomyosarcoma 25 (11.8%) 9 (7.9%) 16 (16.5%)
Sarcoma NOS 16 (7.6%) 9 (7.9%) 7 (7.2%)
Dermatofibrosarcoma 16 (7.6%) 11 (9.6%) 5 (5.2%)
Others 55 (26.1%) 30 (26.3%) 25 (25.8%)
Relapse free survival (years) 2.40 2.46 2.16 0.04
NOS: Not Otherwise Specified
GIST: Gastro Intestinal Stromal Tumours
Perrier et al. BMC Health Services Research 2012, 12:82
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Page 5 of 8Another weakness was the lack of information on
potentially confounding variables such as the initial per-
formance status of the patient, the cumulative volume
for the surgeon and the hospital, the type of provider
(academic cancer centre, non academic cancer centre,
non academic non cancer centre) [26-28] that could not
be controlled for in the statistical analysis. Any resulting
bias, however, would have tended to cause an underesti-
mation rather than an overestimation of the true effect
of compliance, since in the CPG + group the costs of
diagnosis were higher (Table 4) despite a lower grade of
tumours (Table 3).
Interestingly, the higher overall cost involved in diag-
nosing patients according to CPGs was accounted for
almost entirely by increased hospitalisation (rather than
by greater use of imaging or biopsy or external consulta-
tions) (Table 4). The average cost of hospitalization was
€4,097 in CPG + and €2,317 in CPG- groups. The
difference corresponds to 2.3 additional days of hospital
stay at the prevailing daily cost of €760 per day (Table
2). Adherence to CPGs requires that decisions be made
within a multidisciplinary committee, and it is likely
that patients’ hospitalization was prolonged in order to
schedule the multidisciplinary meeting needed to reach
a consensus on treatment.
A greater adherence to CPGs during diagnosis appears
to decrease all subsequent costs, notably those of sur-
gery and chemotherapy, probably by reducing the need
for surgical re-intervention or more intense use of anti-
neoplastic drugs (Table 4). Surgery and chemotherapy
were the main factors driving the cost of initial treat-
ment, representing about 66% of the overall cost in the
CPG + group ((7,397 + 5,164)/19,175) and 76% ((9,075
+ 7,207)/21,502) in the CPG- group.
In contrast to other studies that have shown it may be
cheaper in the short term to deviate from CPGs [29],
Table 4 Average costs for each phase of sarcoma management by group (in €, 2009)
Phases of treatment All patients CPG (+) CPG (-) p
Diagnosis overall 3,701 (7420) 4,536 (8,908) 2,728 (5,095) 0.07
hospitalization 3,275 (7,376) 4,097 (8,791) 2,317 (4,701) 0.07
imaging 259 (198) 274 (210) 241 (182) 0.21
biopsy 93 (57) 88 (45) 99 (69) 0.15
consultation 74 (96) 77 (88) 71 (105) 0.64
Surgery overall 8,170 (7,364) 7,397 (6,034) 9,075 (8,639) 0.09
hospitalization 7,927 (7,101) 7,163 (5,773) 8,821 (8,363) 0.09
imaging 95 (163) 108 (179) 80 (141) 0.21
transfusion 148 (384) 126 (384) 174 (386) 0.36
Chemo-therapy overall 6,107 (11,988) 5,164 (11,197) 7,207 (13,123) 0.22
hospitalization 3,913 (8,568) 2,938 (7,176) 5,050 (9,905) 0.07
consultation 59 (405) 81 (545) 35 (98) 0.39
transfusion 56 (223) 53 (228) 60 (220) 0.20
drugs 1,956 (5,171) 1,982 (5,964) 1,925 (4,115) 0.94
imaging 123 (279) 110 (277) 137 (284) 0.48
Radio-therapy overall 2,270 (5,850) 2,078 (5,599) 2,493 (6,173) 0.60
hospitalization 1,544 (5,223) 1,449 (4,867) 1,656 (5,658) 0.77
sessions 726 (1,266) 629 (1,269) 837 (1,262) 0.23
Initial treatment 20,248 (18,474) 19,175 (17,555) 21,502 (19,778) 0.36
Follow Up 5,048 (11,760) 4,396 (12,343) 5,811 (11,116) 0.38
Overall management 25,296 (22,919) 23,571 (21,913) 27,313 (24,403) 0.23
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Page 6 of 8the present study found that compliance with CPGs
strictly dominates for relapse-free survival, meaning that
management of sarcoma according to CPGs is less
costly and more effective. This evidence should encou-
rage health providers to promote adherence to guide-
lines since adopting this approach achieves a better
q u a l i t yo fc a r ea n di sam o r e efficient allocation of
resources. It should also encourage compliance among
physicians, some of whom perceive CPGs as limiting
their freedom to make diagnostic and therapeutic
decisions.
Compliance with CPGs in sarcoma management has
increased since 2001. A retrospective study of the medi-
cal records of sarcoma patients in the University Hospi-
tal of Lyon and the Cancer Centre Léon Bérard found
that between 1999 and 2001 initial clinical management
had been consistent with the CPG in only 32% of cases
[12]. In this study, the compliance rate reached 54%.
Compliance with guidelines was greater for chemother-
apy than for other aspects of sarcoma management
since detailed protocols are more common than in diag-
nosis, surgery, radiotherapy or follow up. Compliance
with CPGs was also more frequent for low-grade than
for high-grade sarcomas (p = 0.01); and it has been sug-
gested that physicians are less likely to adhere to CPGs
if they believe that compliance will not improve out-
come [30]. Compliance was also better for GIST than
for other histologies, probably because imatinib and
related drugs have led to a remarkable improvement in
management on which there is global consensus [31].
Conclusions
The present findings should encourage physicians’
efforts to increase their compliance with CPGs and
encourage healthcare administrators to invest in imple-
menting CPGs in the management of sarcoma.
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Appendix A. Annexe 1. Main CPG criteria for each sequence of initial
sarcoma treatment
Main Criteria for diagnosis: Clinical size and depth of the tumour mass must
be recorded; Computed Tomography (CT) is required for abdominal
localizations, or Magnetic Resonance Imaging (MRI) for limb localizations;
Chest radiograph or CT scan is required to identify metastases; Initial biopsy
(incisional or needle), preferably by the surgeon in charge of future surgical
procedures, is required for bone and soft tissue sarcomas, with the
exception of small tumours (< 3 cm) for which excisional biopsy is
considered appropriate.
Main Criteria for surgery: Whenever possible, primary surgery should involve
a wide excision with 1-2 cm margins. For high-grade, large (> 3 cm) or
deep-seated tumours, surgery alone is acceptable only in case of
amputation or compartmental resection with negative histological margins
(R0). Wide excision alone, with no adjuvant treatment, is acceptable only for
superficial, small (< 3 cm) and low-grade lesions. Histologically positive
margins (R1) or incomplete excision (R2) have to be considered inadequate,
and should be followed by further appropriate treatment.
Main criteria for chemotherapy: For non-readily operable sarcomas, primary
chemotherapy or radiation therapy can be an option. For readily operable
sarcomas, neo-adjuvant chemotherapy should be performed only as part of
a clinical research protocol. In the adjuvant setting, systemic chemotherapy
should be performed only within the context of a prospective clinical trial.
Adjuvant chemotherapy can be performed for patients with histologically
positive margins after wide surgical excision.
Main criteria for radiation therapy: Association of wide surgical excision and
adjuvant radiation therapy should be considered the standard treatment.
The absence of adjuvant radiotherapy is acceptable for superficial, small (< 3
cm) and low-grade tumours, and for limb sarcomas when amputation is
performed. For non-operable sarcomas, primary radiation therapy could be
an option. The optimal treatment strategy involves a 50 Gy delivered dose
with an additional boost of 10 Gy in case of microscopic residual tumour
(R1), with a target volume encompassing the tumour bed and surgical scars,
including draining orifices, with adapted security margins. Moreover, the
interval from surgery to radiation therapy must not be longer than 8 weeks.
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